The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

Canadian Journal of Ophthalmology

Volumn 44, Issue 2, 2009, Pages 154-159

  Ahmadi, Amir Ali ^a   Chuo, Jean Y ^a   Banashkevich, Alexander ^a   Ma, Patrick E ^a   Maberley, David A L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Avastin; Bevacizumab; Branch retinal vein occlusion; Macular edema; Optical coherence tomography; Visual acuity

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CANADA; CATARACT; CLINICAL ARTICLE; DRUG EFFECT; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; PATIENT REFERRAL; RETINA; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; RETROSPECTIVE STUDY; SIDE EFFECT; THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

EID: 66249083148     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-040     Document Type: Article

References (40)

1. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429-41.
2. The Eye Disease Case-control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-96.
3. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusion. Arch Ophthalmol 1982;100:1132-40.
4. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossing in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298-302.
5. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL. The distribution of angioarchitectural changes within the vicinity of arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998;105:424-27.
6. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis-a pathological report. Trans Ophthalmol Soc U K 1969;88:191-210.
7. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol 1988;106:1469-71.
8. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993;100:423-8.
9. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999;19:1-5.
10. Tang WM, Han DP. A study of surgical approaches to retinal vascular occlusions. Arch Ophthalmol 2000;118:138-43.
11. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch retinal vein occlusion. Am J Ophthalmol 1984;98:271-82.
12. The Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986;104:34-41.
13. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999;237:1024-7.
14. Barbazetto IA, Schmidt-Erfurth UM. Evaluation of functional defects in branch retinal vein occlusion before and after laser treatment with scanning laser perimetry. Ophthalmology 2000;107:1089-98.
15. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
16. 16. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-45.
17. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-8.
18. Spandau U, Wickenháuser A, Rensch F, Jonas J. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-9.
19. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
20. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
22. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
23. Iturralde D, Spaide RF, Meyerle CB, et al. Intervitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. Retina 2006;26:279-84.
24. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-13.
25. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-6.
26. Rabena MD, Pieramicci DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-25.
27. Ahmadieh H, Moradian S, Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 2005;26:191-3.
28. Schaal KB, Höh AE, Scheuerle A, Schütt F, Dithmar S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion [in German]. Ophthalmologe 2007;104:285-9.
29. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-54.
30. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-9.
31. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-22.
32. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-5.
33. Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008;19:234-8.
34. Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 2008;22:1168-71.
35. Esrick E, Subramanian ML, Heier JS, et al. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 2005;139:653-7.
36. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-83.
37. Cekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-5.
38. Cekiç O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139:993-8.
39. Jonas J, Heatley G, Spaide R, Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 2005;14:168-171.
40. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-3.